Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
Expert Ratings For Ocular Therapeutix
Ocular Therapeutix (NASDAQ:OCUL) has observed the following analyst ratings within the last quarter:
JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $30
JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and raises the price target from $27 to $30.
Ocular Therapeutix: Q3 Earnings Insights
Ocular Therapeutix (NASDAQ:OCUL) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM.
Here's what investors need to know about the announcement.
Ocular Therapeutix Q3 Sales $12.15M Miss $12.45M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly sales of $12.15 million which missed the analyst consensus estimate of $12.45 million by 2.41 percent. This is a 106.77 percent increase over sales of $5.88 million
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
Ocular Therapeutix Announces Update From Centers For Medicare And Medicaid Services For Reimbursement Of DEXTENZA
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced that the